O “Wegova oral” – A version of Semaglutida in tablet – led to a weight loss of 16.6% in people with obesity, according to a new study released by new pharmacist Nordisk last week and published in The New England Journal of Medicine.
Evaluated the effectiveness and safety of the 25 mg oral semaglutado, popularly known as “Wegova oral“or”WEGOVY IN COMMISH“In 307 adults with obesity or overweight that had one or more weight -related comorbidities, but they had no diabetes.
The results showed that when patients joined treatment well, the average weight loss went 16.6% for the group that took the oral Wegovy compared to 2.7% for those who received placebo.
In addition, more than one third (34.4%) of participants reached a reduction of 20% or more of body weight, against only 2.9% in the placebo group. According to the researchers, this result is comparable to those obtained in studies previously done with the.
According to the study, even when patients did not take the medically as prescribed, those who received oral Wegovy had an average weight loss of 13.6% compared to 2.2% with placebo. Almost one third (29.7%) reached weight loss of 20% or more, versus 3.3% in the placebo group.
Another point analyzed by the study was: the tablet reduced risk factors for heart and vascular health associated with obesity, and has improved the ability of patients to perform activities in everyday life.
“The arrival of an oral formulation of high effectiveness for the treatment of obesity is a milestone that reflects our commitment to listen and meet the needs of patients,” says Marília Fonseca, medical director of Novo Nordisk in Brazil, in a press release.
“We know that the preference for oral treatment can be a decisive factor for many people, and offer an option that combines the convenience of a daily pill with 16.6%robust weight loss, already known to Semaglutado, has the potential to expand access and adherence to treatment,” he adds.
Regarding side effects, the oral version of Wegovy presented events similar to those of the pen version: nausea and vomiting were the most common, usually with mild to moderate and transient severity.
Side effects that led patients to give up the treatment were 6.9%. And the incidence of serious adverse events was 3.9%.
Novo Nordisk has submitted a new drug (NDA) request for Wegovy’s daily use tablet for Food and Drug Administration (FDA), the United States Regulatory Agency. The analysis should be completed by the end of 2025. The company should submit the drug for analysis of the National Health Surveillance Agency (Anvisa) soon.
Wegovy Oral and Rybelsus: What’s the difference?
This is not the first formulation of Semaglutida – active ingredient of and wegovy – in oral version. The Rybelsus tablet is also made based on the molecule, but on a smaller dosage (14 mg) and indicated for the treatment of type 2 diabetes.
In other words, Rybelsus is the “oral” version of Ozepic, a penalty pen for diabetes treatment. Already the 25 mg semaglute in tablet is the “oral” version of the Wegovy pen. The trade name of the drug has been submitted to FDA and is pending approval, according to new Nordisk.
